The main objective of WP4 is to assess the validity and usefulness of omics signatures identified and validated in WPs 1, 2 and 3 for improved identification and risk stratification of patients with EHBP and stratification of patients with PHT.

The specific objectives of the WP are:

  1. To compare the diagnostic accuracy of omics-based signatures for identifying patients with EHBP compared with standard procedures.
  2. To determine the prognostic value of the omics signatures by assessing their relationship with outcome measures after one year follow-up, including BP, BP related target organ damage (TOD) and QoL.
  3. To assess the potential usefulness of the omics signatures for stratification of patients with PHT.
  4. To relate the use of omics signatures to the social impact of hypertension, including QoL, degree of psychosocial burden, patients’ lives and economic effects.


Scientific Coordinator: Dr Maria -Christina Zennaro, Head of INSERM U970 team 14: Genetic mechanisms of aldosterone-related disorders.

Project Manager (INSERM-Transfert): Catherine Clusel

Project Manager (INSERM-Transfert): Kristina Fiedler

More contact details here


Paris Cardiovascular Research Center (PARCC), European Georges Pompidou Hospital, 56 rue Leblanc, 75015 Paris, France

INSERM-Transfert, Paris Biopark, 7 rue Watt, 75013 Paris, France


European Georges Pompidou Hospital

View Larger Map


View Larger Map

Go to top
JSN Blank template designed by